Compass Pathways PLC
NASDAQ:CMPS

Watchlist Manager
Compass Pathways PLC Logo
Compass Pathways PLC
NASDAQ:CMPS
Watchlist
Price: 4.41 USD -0.9% Market Closed
Market Cap: 301.6m USD
Have any thoughts about
Compass Pathways PLC?
Write Note

Compass Pathways PLC
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Compass Pathways PLC
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Compass Pathways PLC
NASDAQ:CMPS
Stock-Based Compensation
$17.3m
CAGR 3-Years
-1%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Stock-Based Compensation
$11.2m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Stock-Based Compensation
ÂŁ32.5m
CAGR 3-Years
58%
CAGR 5-Years
117%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Compass Pathways PLC
Glance View

Market Cap
301.7m USD
Industry
Biotechnology

Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.

CMPS Intrinsic Value
2.81 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Compass Pathways PLC's Stock-Based Compensation?
Stock-Based Compensation
17.3m USD

Based on the financial report for Dec 31, 2023, Compass Pathways PLC's Stock-Based Compensation amounts to 17.3m USD.

What is Compass Pathways PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
65%

Over the last year, the Stock-Based Compensation growth was 32%. The average annual Stock-Based Compensation growth rates for Compass Pathways PLC have been -1% over the past three years , 65% over the past five years .

Back to Top